Anadrol Blood Work: Blood Pressure, Liver and the 50 mg Question

Anadrol raises blood pressure through three stacked mechanisms: sodium and water retention via mineralocorticoid activity (oxymetholone uniquely activates the mineralocorticoid receptor among common orals), rapid intracellular water load in muscle tissue, and endothelial effects from the rapid hematocrit rise. The result is the fastest BP climb of any common oral. Users at 50 mg/day typically see systolic rise 10-20 mmHg within the first two weeks, and self-measured morning BP is the only practical way to see it coming.

The mineralocorticoid receptor activation is not just a lab curiosity. It drives renal sodium reabsorption and potassium excretion, which is why some users report muscle cramps that do not respond to magnesium. On Anadrol, potassium losses can be significant, and low potassium worsens the BP response. Practical countermeasures: increase water to 5-6 liters daily, add 3-5 grams of potassium from food (potatoes, spinach, avocado) unless renal function is impaired, and keep sodium moderate but not zero. A sudden drop in sodium intake can trigger a rebound aldosterone effect. The BP cuff is the final judge; if systolic is climbing despite these measures, the dose is too high or the compound is not for you.

The clinical threshold matters less than the trajectory. A systolic that settles at 135-140 with full adaptation is manageable; a systolic climbing 5 mmHg per week at week 3 is not, regardless of the absolute value. Sustained systolic above 150 on cycle is the point where the risk conversation changes from "monitoring" to "the compound is causing vascular damage faster than the cycle is worth.

The trajectory rule only works if your measurement method is consistent. Use the same arm, same time of day, after 5 minutes of seated rest, with the cuff at heart level. Morning readings before food and caffeine are the most reproducible. Do not rely on a single reading; average three, one minute apart. If you see a single spike to 160, that is not a stop signal unless it repeats. But a weekly average that moves from 130 to 138 to 145 over three weeks is a clear trend. Also note that Anadrol can cause a white coat effect in the clinic; home readings are more honest. If home systolic is 140 but clinic is 160, trust the home average and the trend.

Oxymetholone is 17-alpha-alkylated and sits among the most hepatotoxic orals in common use. Superdrol and Halotestin are harsher, but nothing used at 50 mg/day loads the liver faster than Anadrol. ALT and AST typically rise 2-5x baseline by week 4-6 at 50 mg/day. The elevation pattern matters: oxymetholone can produce a cholestatic picture, with GGT and ALP rising together with bilirubin. Its package insert historically warned about peliosis hepatis and hepatocellular tumors with prolonged use. Those are rare outcomes, but they belong to this compound's risk ledger, not to generic "orals are bad" folklore.

ALT and AST are the headline markers, but GGT and bilirubin add context. GGT rises with bile duct pressure and is more specific to cholestasis, which Anadrol can cause. Bilirubin elevation, especially direct bilirubin, indicates impaired excretion. If ALT is 150 but GGT and bilirubin are normal, the damage is hepatocellular and reversible. If GGT is also elevated, a bile acid binder like cholestyramine is sometimes used, but that's a prescription decision for a licensed medical professional, not something to add on your own. The pattern matters: a slow rise over weeks is different from a sudden spike. A single ALT of 200 at week 2 may be a lab error or a transient response; repeat in 3 days. But an ALT that doubles from week 3 to week 4 is a stop signal, not a reason to push through.

Run 4-6 weeks, not 8+. Include TUDCA at 500-1000 mg/day from day one, and treat ALT above 3x baseline (120 U/L) as a stop signal rather than a "keep watching" number. On Anadrol, waiting until week 8 to check the liver is waiting until after the damage curve steepens.

TUDCA at 500-1000 mg/day is the standard, but timing matters. Take it with food, split into two doses, and start a week before the cycle to load the liver. Milk thistle (silymarin) is weaker and does not have the same bile acid modulation; it is not a substitute. If ALT does spike above 3x baseline, stop Anadrol immediately and continue TUDCA for two weeks. Do not add more liver stressors like acetaminophen or alcohol. Also note that fasting can transiently raise ALT; always draw labs in a fasted state, and avoid training the day before. A post-workout draw can show ALT 20-30% higher. Consistency in lab conditions is as important as the absolute number.

Anadrol is one of the great confusions in AAS pharmacology. It does not aromatize, yet it produces the most notorious estrogen-like bloat of any oral. The current best explanation is that oxymetholone acts as a selective estrogen receptor modulator, activating estrogen receptor signaling directly at tissue level without appearing in the E2 blood measurement. The blood work confirms the paradox users live: gyno-adjacent nipple sensitivity and heavy water retention at E2 values of 15-25 pg/mL that would be unremarkable on testosterone.

The SERM-like activity explains why Anadrol can cause gynecomastia in some men even with normal E2. It binds to estrogen receptors in breast tissue and can trigger proliferation without aromatization. This is why an AI does not prevent Anadrol gyno. If you have actual gyno symptoms, not just bloat, a SERM like raloxifene is the usual approach, but the choice and dose are a licensed medical professional's call, not something to self-administer. The bloat is not estrogen, but the breast tissue response can be. Also, the SERM-like effect on bone is why Anadrol was used for osteoporosis; it preserves bone density. That is a side benefit, but it does not change the cardiovascular risk profile.

The practical consequence: an aromatase inhibitor does nothing for Anadrol bloat, because there is nothing to inhibit. If E2 is measured and normal, the bloat is coming from mineralocorticoid activity and SERM-like tissue effects. That means sodium management, hydration discipline, and BP control are the actual interventions. Tamoxifen for Anadrol-related sensitivity is pharmacologically incoherent: it blocks the receptor Anadrol may be activating, but the interplay is unpredictable.

🔬

One of the most common Anadrol stack errors is adding an AI to control the bloat. The E2 comes back in a perfectly normal range, the AI has now crashed real estrogen signaling, and the bloat is unchanged — because it was never aromatase-driven. Measure E2 before you touch an AI on this compound.

The forum default of 50 mg/day is a historical artifact: it was the tablet size, not a pharmacological optimum. The dose-response on harm is steeper than on growth. Going 25 → 50 mg roughly doubles hepatic and BP load while adding maybe 20-30% more anabolic effect; going 50 → 100 mg doubles toxicity again for marginal further gains. Most of Anadrol's signature size effect comes from intracellular water and glycogen, which 25 mg delivers nearly as well as 50.

The 25 mg vs 50 mg difference is not just about toxicity. At 25 mg, the BP rise is typically 5-10 mmHg systolic; at 50 mg, it is 10-20. The anabolic difference is smaller than the toxicity difference. Many users report that 25 mg with a strong base of testosterone gives 80% of the size effect with half the BP and liver load. If you are new to Anadrol, start at 25 mg for the first two weeks, check BP and HCT, then decide. The 50 mg default is for experienced users who know their response. Also, splitting the dose (25 mg morning, 25 mg evening) does not reduce hepatotoxicity because the 17-alpha-alkylation is a first-pass effect; the liver sees the same total daily load.